About US
Contact us
-
Biological data warehouses helps speed up drug development, researchers sayDrawing on patient information from a biological data warehouse has the potential to speed up drug development and cut costs, according to researchers from the Moffitt Cancer Center in the US.The team2013/5/14
-
FDA gives Novartis' Ilaris big boost with nod for rare juvenile arthritisNovartis ($NVS) has grabbed one of two new indications it was shooting for with its rare disease drug Ilaris, one step toward turning the drug into a blockbuster. The FDA approved Ilaris for treatm2013/5/13
-
CFDA specifies relevant issues on written confirmation for active substances exported to EUChina Food and Drug Administration (CFDA) recently issued a notice on relevant issues on written confirmation for active substances exported to EU, which specifies the issuer, the issuance method, and2013/5/13
-
After going it alone, Vivus finally open to Big Pharma sales partnershipWhen Vivus ($VVUS) announced first-quarter earnings yesterday, sales weren't just off of analyst estimates. They also crushed investors' hopes that the company could halt its continued failure to get2013/5/10
-
GlaxoSmithKline, Merck offer GAVI 95% discount on HPV vaccinesGlaxoSmithKline ($GSK) and Merck ($MRK) are slashing the prices of their HPV vaccinations in a deal with the GAVI Alliance, which delivers immunizations to the developing world. It's the first big pu2013/5/10
-
Unhappy with price caps at home, Indian drugmakers eye more U.S. growthIt's no big secret that international drugmakers are miffed at India. Revoking a few drug patents and overriding others will do that. But India's own pharma companies have their own beef with governm2013/5/9
-
Biogen's HQ plans change, thanks to early Tecfidera successWhat happens when a new drug comes charging out of the launch gate? For Biogen Idec ($BIIB), it means a rethink of its real estate plans. Its fast-growing staff won't all fit in the new headquarters2013/5/9
-
Don't confuse Kadcyla with Herceptin, FDA saysThe FDA is picky about drug names. It's been known to reject brand monikers because they're too similar to others already out there in the market, worried that harried physicians and pharmacists migh2013/5/8
-
Merck shows signs of life in consumer health with new promo campaignMerck & Co. hasn't spent huge amounts of time and resources pushing its consumer health business. While other Big Pharmas like Sanofi ($SNY) and GlaxoSmithKline ($GSK) went around the world snapp2013/5/8
-
ALM201 licensed to South Korean pharmaceutical for developmentThe novel anti-angiogenic peptide ALM2012 has been licensed to a South Korean pharmaceutical company for clinical development and marketing. That is according to a statement issued by the Northern Ir2013/5/7